- Home
- ORMP vs CBUS Comparison
ORMP vs CBUS Comparison
Compare ORMP & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORMP | CBUS |
|---|---|---|
| Founded | 2002 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.3M | 121.1M |
| IPO Year | 2010 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ORMP | CBUS |
|---|---|---|
| Price | $4.66 | $1.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 158.2K | ★ 376.0K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | ★ 412.50 | 74.33 |
| EPS | ★ 1.50 | N/A |
| Revenue | $2,000,000.00 | ★ $3,639,000.00 |
| Revenue This Year | N/A | $112.72 |
| Revenue Next Year | N/A | $83.18 |
| P/E Ratio | $3.13 | ★ N/A |
| Revenue Growth | ★ 49.25 | N/A |
| 52 Week Low | $1.98 | $1.09 |
| 52 Week High | $5.01 | $4.19 |
Technical Indicators
Market Signals| Indicator | ORMP | CBUS |
|---|---|---|
| Relative Strength Index (RSI) | 69.57 | 37.14 |
| Support Level | $3.21 | $1.21 |
| Resistance Level | N/A | $1.56 |
| Average True Range (ATR) | 0.22 | 0.11 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 68.64 | 9.59 |
Price Performance
Historical ComparisonAbout ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.